Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:00 PM
Ignite Modification Date: 2025-12-25 @ 2:41 PM
NCT ID: NCT00109850
Description: Only adverse events and serious adverse events that are possibly, probably or definitely related to study drug are reported.
Frequency Threshold: 5
Time Frame: Patients were assessed for adverse events after every two cycles of chemotherapy.
Study: NCT00109850
Study Brief: S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cetuximab+Cisplatin+Irinotecan Followed by RT in Cycle 3 Patients received four 21-day cycles of cetuximab 400 mg/m\^2 (day 1, cycle 1), cetuximab 250 mg/m\^2 (day 8, 15, cycle 1, then days 1, 8 and 15 for subsequent cycles), cisplatin 30 mg/m\^2 (days 1 and 8, all cycles), and irinotecan 65 mg/m\^2 (days 1 and 8, all cycles). Thoracic Radiotherapy (TRT) was administered at 1.8 Gy in 28 daily fractions to a total dose of 50.4 Gy, beginning on day 1 of cycle 3. None None 3 21 21 21 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Necrosis, GI - Colon/cecum/appendix SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Death not associated with CTCAE term - Sudden death SYSTEMATIC_ASSESSMENT General disorders CTCAE (3.0) View
CNS cerebrovascular ischemia SYSTEMATIC_ASSESSMENT Nervous system disorders CTCAE (3.0) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Mucositis/stomatitis (clinical exam) - Oral cavity SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Mucositis/stomatitis (functional/symptomatic) - Oral cavity SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Rash: dermatitis associated with radiation - Chemoradiation SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications CTCAE (3.0) View
Hemoglobin SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (3.0) View
Constipation SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Diarrhea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Dysphagia (difficulty swallowing) SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Esophagitis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Heartburn/dyspepsia SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Pain - Abdomen NOS SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Pain - Esophagus SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Fatigue (asthenia, lethargy, malaise) SYSTEMATIC_ASSESSMENT General disorders CTCAE (3.0) View
ALT, SGPT (serum glutamic pyruvic transaminase) SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
AST, SGOT (serum glutamic oxaloacetic transaminase) SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Alkaline phosphatase SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Leukocytes (total WBC) SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Lymphopenia SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Neutrophils/granulocytes (ANC/AGC) SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Platelets SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Weight loss SYSTEMATIC_ASSESSMENT Investigations CTCAE (3.0) View
Albumin, serum-low (hypoalbuminemia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Anorexia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Calcium, serum-low (hypocalcemia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Dehydration SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Glucose, serum-high (hyperglycemia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Magnesium, serum-low (hypomagnesemia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Potassium, serum-low (hypokalemia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Sodium, serum-low (hyponatremia) SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Pain - Muscle SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders CTCAE (3.0) View
Neuropathy: sensory SYSTEMATIC_ASSESSMENT Nervous system disorders CTCAE (3.0) View
Taste alteration (dysgeusia) SYSTEMATIC_ASSESSMENT Nervous system disorders CTCAE (3.0) View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders CTCAE (3.0) View
Dry skin SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Hair loss/Alopecia (scalp or body) SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Rash/desquamation SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Rash: acne/acneiform SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Hypotension SYSTEMATIC_ASSESSMENT Vascular disorders CTCAE (3.0) View